Hesen Wu, Xingyi Chen, Xiaoming Feng, Wei He, Duilio Divisi, Jimmy T Efird, José Franco, Xuemin Guo
{"title":"Efficacy of three lung cancer prediction models in diagnosing benign and malignant pulmonary nodules.","authors":"Hesen Wu, Xingyi Chen, Xiaoming Feng, Wei He, Duilio Divisi, Jimmy T Efird, José Franco, Xuemin Guo","doi":"10.21037/tcr-2025-468","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The predictive models for malignant lung nodules have been developed, but need further validation and optimization for broader clinical use. This study aimed to compare the diagnostic efficacy of the Mayo model, Peking University People's Hospital (PKUPH) model, and the lung cancer biomarker panel (LCBP) model in distinguishing between benign and malignant pulmonary nodules, providing valuable clinical research data for the early diagnosis of lung cancer.</p><p><strong>Methods: </strong>Clinical and imaging data of patients diagnosed with pulmonary nodules at Meizhou People's Hospital from March 2021 through January 2023 were collected. Data from patients with benign pulmonary nodules during the same period, who served as negative referents, were also gathered. The Mayo model, PKUPH model, and LCBP model were used to clinically validate lung cancer prediction rates. The receiver operating characteristic (ROC) curves and statistical significance comparing the areas under the curve (AUCs) for each model were evaluated.</p><p><strong>Results: </strong>A total of 428 patients were included: 160 females and 268 males. The noncancer group included 218 cases (50.93%), and the cancer group included 210 cases (49.07%). The AUC values of the three models were as follows: Mayo model, 0.783; PKUPH model, 0.726; and LCBP model, 0.759. (I) For the Mayo model, at the maximum Youden index, the concordance rate was 74.3%, the sensitivity 85.71%, the specificity 63.30%, the positive predictive value 69.23%, the negative predictive value 82.14%, the positive likelihood ratio 2.335, and the negative likelihood ratio 0.226. (II) For the PKUPH model, at the maximum Youden index, the concordance rate was 70.3%, the sensitivity 84.29%, the specificity 56.88%, the positive predictive value 65.31%, the negative predictive value 78.98%, the positive likelihood ratio 1.955, and the negative likelihood ratio 0.276. (III) For the LCBP model, at the maximum Youden index, the concordance rate was 75.0%, the sensitivity 72.38%, the specificity 77.52%, the positive predictive value 75.62%, the negative predictive value 74.45%, the positive likelihood ratio 3.220, and the negative likelihood ratio 0.356.</p><p><strong>Conclusions: </strong>All three predictive models exhibit clinical applicability, with minimal differences in diagnostic efficacy. The LCBP model outperformed both the Mayo and PKUPH models in diagnostic performance, showing greater diagnostic value for the Chinese population. However, there is still room for optimization in each model.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 4","pages":"2410-2420"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2025-468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The predictive models for malignant lung nodules have been developed, but need further validation and optimization for broader clinical use. This study aimed to compare the diagnostic efficacy of the Mayo model, Peking University People's Hospital (PKUPH) model, and the lung cancer biomarker panel (LCBP) model in distinguishing between benign and malignant pulmonary nodules, providing valuable clinical research data for the early diagnosis of lung cancer.
Methods: Clinical and imaging data of patients diagnosed with pulmonary nodules at Meizhou People's Hospital from March 2021 through January 2023 were collected. Data from patients with benign pulmonary nodules during the same period, who served as negative referents, were also gathered. The Mayo model, PKUPH model, and LCBP model were used to clinically validate lung cancer prediction rates. The receiver operating characteristic (ROC) curves and statistical significance comparing the areas under the curve (AUCs) for each model were evaluated.
Results: A total of 428 patients were included: 160 females and 268 males. The noncancer group included 218 cases (50.93%), and the cancer group included 210 cases (49.07%). The AUC values of the three models were as follows: Mayo model, 0.783; PKUPH model, 0.726; and LCBP model, 0.759. (I) For the Mayo model, at the maximum Youden index, the concordance rate was 74.3%, the sensitivity 85.71%, the specificity 63.30%, the positive predictive value 69.23%, the negative predictive value 82.14%, the positive likelihood ratio 2.335, and the negative likelihood ratio 0.226. (II) For the PKUPH model, at the maximum Youden index, the concordance rate was 70.3%, the sensitivity 84.29%, the specificity 56.88%, the positive predictive value 65.31%, the negative predictive value 78.98%, the positive likelihood ratio 1.955, and the negative likelihood ratio 0.276. (III) For the LCBP model, at the maximum Youden index, the concordance rate was 75.0%, the sensitivity 72.38%, the specificity 77.52%, the positive predictive value 75.62%, the negative predictive value 74.45%, the positive likelihood ratio 3.220, and the negative likelihood ratio 0.356.
Conclusions: All three predictive models exhibit clinical applicability, with minimal differences in diagnostic efficacy. The LCBP model outperformed both the Mayo and PKUPH models in diagnostic performance, showing greater diagnostic value for the Chinese population. However, there is still room for optimization in each model.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.